Functional consequences of the human cardiac troponin I hypertrophic cardiomyopathy mutation R145G in transgenic mice

Yuhui Wen, Jose Renato Pinto, Aldrin V. Gomes, Yuanyuan Xu, Yingcai Wang, Ying Wang, James D. Potter, W. Glenn Kerrick

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

In this study, we addressed the functional consequences of the human cardiac troponin I (hcTnI) hypertrophic cardiomyopathy R145G mutation in transgenic mice. Simultaneous measurements of ATPase activity and force in skinned papillary fibers from hcTnI R145G transgenic mice (Tg-R145G) versus hcTnI wild type transgenic mice (Tg-WT) showed a significant decrease in the maximal Ca2+-activated force without changes in the maximal ATPase activity and an increase in the Ca2+ sensitivity of both ATPase and force development. No difference in the cross-bridge turnover rate was observed at the same level of cross-bridge attachment (activation state), showing that changes in Ca2+ sensitivity were not due to changes in cross-bridge kinetics. Energy cost calculations demonstrated higher energy consumption in Tg-R145G fibers compared with Tg-WT fibers. The addition of 3mM 2,3-butanedione monoxime at pCa 9.0 showed that there was ∼2-4% of force generating cross-bridges attached in Tg-R145G fibers compared with less than 1.0% in Tg-WT fibers, suggesting that the mutation impairs the ability of the cardiac troponin complex to fully inhibit cross-bridge attachment under relaxing conditions. Prolonged force and intracellular [Ca2+] transients in electrically stimulated intact papillary muscles were observed in Tg-R145G compared with Tg-WT. These results suggest that the phenotype of hypertrophic cardiomyopathy is most likely caused by the compensatory mechanisms in the cardiovascular system that are activated by 1) higher energy cost in the heart resulting from a significant decrease in average force per cross-bridge, 2) slowed relaxation (diastolic dysfunction) caused by prolonged [Ca2+] and force transients, and 3) an inability of the cardiac TnI to completely inhibit activation in the absence of Ca2+ in Tg-R145G mice.

Original languageEnglish
Pages (from-to)20484-20494
Number of pages11
JournalJournal of Biological Chemistry
Volume283
Issue number29
DOIs
StatePublished - Jul 18 2008

Fingerprint

Troponin I
Hypertrophic Cardiomyopathy
Transgenic Mice
Adenosine Triphosphatases
Mutation
Fibers
Costs and Cost Analysis
Troponin
Papillary Muscles
Cardiovascular System
Chemical activation
Phenotype
Cardiovascular system
Muscle
Costs
Energy utilization
Kinetics

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Functional consequences of the human cardiac troponin I hypertrophic cardiomyopathy mutation R145G in transgenic mice. / Wen, Yuhui; Pinto, Jose Renato; Gomes, Aldrin V.; Xu, Yuanyuan; Wang, Yingcai; Wang, Ying; Potter, James D.; Kerrick, W. Glenn.

In: Journal of Biological Chemistry, Vol. 283, No. 29, 18.07.2008, p. 20484-20494.

Research output: Contribution to journalArticle

Wen, Yuhui ; Pinto, Jose Renato ; Gomes, Aldrin V. ; Xu, Yuanyuan ; Wang, Yingcai ; Wang, Ying ; Potter, James D. ; Kerrick, W. Glenn. / Functional consequences of the human cardiac troponin I hypertrophic cardiomyopathy mutation R145G in transgenic mice. In: Journal of Biological Chemistry. 2008 ; Vol. 283, No. 29. pp. 20484-20494.
@article{531d570a2a834beb9f2491488dbe05b3,
title = "Functional consequences of the human cardiac troponin I hypertrophic cardiomyopathy mutation R145G in transgenic mice",
abstract = "In this study, we addressed the functional consequences of the human cardiac troponin I (hcTnI) hypertrophic cardiomyopathy R145G mutation in transgenic mice. Simultaneous measurements of ATPase activity and force in skinned papillary fibers from hcTnI R145G transgenic mice (Tg-R145G) versus hcTnI wild type transgenic mice (Tg-WT) showed a significant decrease in the maximal Ca2+-activated force without changes in the maximal ATPase activity and an increase in the Ca2+ sensitivity of both ATPase and force development. No difference in the cross-bridge turnover rate was observed at the same level of cross-bridge attachment (activation state), showing that changes in Ca2+ sensitivity were not due to changes in cross-bridge kinetics. Energy cost calculations demonstrated higher energy consumption in Tg-R145G fibers compared with Tg-WT fibers. The addition of 3mM 2,3-butanedione monoxime at pCa 9.0 showed that there was ∼2-4{\%} of force generating cross-bridges attached in Tg-R145G fibers compared with less than 1.0{\%} in Tg-WT fibers, suggesting that the mutation impairs the ability of the cardiac troponin complex to fully inhibit cross-bridge attachment under relaxing conditions. Prolonged force and intracellular [Ca2+] transients in electrically stimulated intact papillary muscles were observed in Tg-R145G compared with Tg-WT. These results suggest that the phenotype of hypertrophic cardiomyopathy is most likely caused by the compensatory mechanisms in the cardiovascular system that are activated by 1) higher energy cost in the heart resulting from a significant decrease in average force per cross-bridge, 2) slowed relaxation (diastolic dysfunction) caused by prolonged [Ca2+] and force transients, and 3) an inability of the cardiac TnI to completely inhibit activation in the absence of Ca2+ in Tg-R145G mice.",
author = "Yuhui Wen and Pinto, {Jose Renato} and Gomes, {Aldrin V.} and Yuanyuan Xu and Yingcai Wang and Ying Wang and Potter, {James D.} and Kerrick, {W. Glenn}",
year = "2008",
month = "7",
day = "18",
doi = "10.1074/jbc.M801661200",
language = "English",
volume = "283",
pages = "20484--20494",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "29",

}

TY - JOUR

T1 - Functional consequences of the human cardiac troponin I hypertrophic cardiomyopathy mutation R145G in transgenic mice

AU - Wen, Yuhui

AU - Pinto, Jose Renato

AU - Gomes, Aldrin V.

AU - Xu, Yuanyuan

AU - Wang, Yingcai

AU - Wang, Ying

AU - Potter, James D.

AU - Kerrick, W. Glenn

PY - 2008/7/18

Y1 - 2008/7/18

N2 - In this study, we addressed the functional consequences of the human cardiac troponin I (hcTnI) hypertrophic cardiomyopathy R145G mutation in transgenic mice. Simultaneous measurements of ATPase activity and force in skinned papillary fibers from hcTnI R145G transgenic mice (Tg-R145G) versus hcTnI wild type transgenic mice (Tg-WT) showed a significant decrease in the maximal Ca2+-activated force without changes in the maximal ATPase activity and an increase in the Ca2+ sensitivity of both ATPase and force development. No difference in the cross-bridge turnover rate was observed at the same level of cross-bridge attachment (activation state), showing that changes in Ca2+ sensitivity were not due to changes in cross-bridge kinetics. Energy cost calculations demonstrated higher energy consumption in Tg-R145G fibers compared with Tg-WT fibers. The addition of 3mM 2,3-butanedione monoxime at pCa 9.0 showed that there was ∼2-4% of force generating cross-bridges attached in Tg-R145G fibers compared with less than 1.0% in Tg-WT fibers, suggesting that the mutation impairs the ability of the cardiac troponin complex to fully inhibit cross-bridge attachment under relaxing conditions. Prolonged force and intracellular [Ca2+] transients in electrically stimulated intact papillary muscles were observed in Tg-R145G compared with Tg-WT. These results suggest that the phenotype of hypertrophic cardiomyopathy is most likely caused by the compensatory mechanisms in the cardiovascular system that are activated by 1) higher energy cost in the heart resulting from a significant decrease in average force per cross-bridge, 2) slowed relaxation (diastolic dysfunction) caused by prolonged [Ca2+] and force transients, and 3) an inability of the cardiac TnI to completely inhibit activation in the absence of Ca2+ in Tg-R145G mice.

AB - In this study, we addressed the functional consequences of the human cardiac troponin I (hcTnI) hypertrophic cardiomyopathy R145G mutation in transgenic mice. Simultaneous measurements of ATPase activity and force in skinned papillary fibers from hcTnI R145G transgenic mice (Tg-R145G) versus hcTnI wild type transgenic mice (Tg-WT) showed a significant decrease in the maximal Ca2+-activated force without changes in the maximal ATPase activity and an increase in the Ca2+ sensitivity of both ATPase and force development. No difference in the cross-bridge turnover rate was observed at the same level of cross-bridge attachment (activation state), showing that changes in Ca2+ sensitivity were not due to changes in cross-bridge kinetics. Energy cost calculations demonstrated higher energy consumption in Tg-R145G fibers compared with Tg-WT fibers. The addition of 3mM 2,3-butanedione monoxime at pCa 9.0 showed that there was ∼2-4% of force generating cross-bridges attached in Tg-R145G fibers compared with less than 1.0% in Tg-WT fibers, suggesting that the mutation impairs the ability of the cardiac troponin complex to fully inhibit cross-bridge attachment under relaxing conditions. Prolonged force and intracellular [Ca2+] transients in electrically stimulated intact papillary muscles were observed in Tg-R145G compared with Tg-WT. These results suggest that the phenotype of hypertrophic cardiomyopathy is most likely caused by the compensatory mechanisms in the cardiovascular system that are activated by 1) higher energy cost in the heart resulting from a significant decrease in average force per cross-bridge, 2) slowed relaxation (diastolic dysfunction) caused by prolonged [Ca2+] and force transients, and 3) an inability of the cardiac TnI to completely inhibit activation in the absence of Ca2+ in Tg-R145G mice.

UR - http://www.scopus.com/inward/record.url?scp=50649125630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50649125630&partnerID=8YFLogxK

U2 - 10.1074/jbc.M801661200

DO - 10.1074/jbc.M801661200

M3 - Article

C2 - 18430738

AN - SCOPUS:50649125630

VL - 283

SP - 20484

EP - 20494

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 29

ER -